Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pone.0001148
DC FieldValue
dc.titleEffects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial
dc.contributor.authorPan A.
dc.contributor.authorSun J.
dc.contributor.authorChen Y.
dc.contributor.authorYe X.
dc.contributor.authorLi H.
dc.contributor.authorYu Z.
dc.contributor.authorWang Y.
dc.contributor.authorGu W.
dc.contributor.authorZhang X.
dc.contributor.authorChen X.
dc.contributor.authorWendy D.-W.
dc.contributor.authorLiu Y.
dc.contributor.authorLin X.
dc.date.accessioned2019-11-08T00:57:56Z
dc.date.available2019-11-08T00:57:56Z
dc.date.issued2007
dc.identifier.citationPan A., Sun J., Chen Y., Ye X., Li H., Yu Z., Wang Y., Gu W., Zhang X., Chen X., Wendy D.-W., Liu Y., Lin X. (2007). Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: A randomized, double-blind, cross-over trial. PLoS ONE 2 (11) : e1148. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0001148
dc.identifier.issn19326203
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161861
dc.description.abstractBackground. Flaxseed consumption has been shown to improve blood lipids in humans and flaxseed-derived lignan has been shown to enhance glycemic control in animals. The study aimed to investigate the effect of a flaxseed-derived lignan supplement on glycemic control, lipid profiles and insulin sensitivity in type 2 diabetic patients. Methodology/Principal Findings. This was a randomized, double-blind, placebo-controlled, cross-over trial and it was conducted between April and December 2006 in Shanghai, China. Seventy-three type 2 diabetic patients with mild hypercholesterolemia were enrolled into the study. Patients were randomized to supplementation with flaxseed-derived lignan capsules (360 mg lignan per day) or placebo for 12 weeks, separated by an 8-week wash-out period. HbA1c, lipid profiles, insulin resistance index and inflammatory factors were measured. Sixty-eight completed the study and were included in the analyses. The lignan supplement significantly improved glycemic control as measured by HbA1c (-0.10�65 % vs. 0.09�52 %, P=0.001) compared to placebo; however no significant changes were observed in fasting glucose and insulin concentrations, insulin resistance and blood lipid profiles. Urinary excretion of lignan metabolites (enterodiol and enterolactone) was significantly higher after the lignan supplement intervention compared to baseline (14.2�.1 vs. 1.2=2.4 ?g/mL, P<0.001). Data also suggested minimal competition between lignan and isoflavones for bioavailability when measured by the excretion concentrations. Conclusions/Significance. Daily lignan supplementation resulted in modest, yet statistically significant improvements in glycemic control in type 2 diabetic patients without apparently affecting fasting glucose, lipid profiles and insulin sensitivity. Further studies are needed to validate these findings and explore the efficacy of lignans on type 2 diabetes. � 2007 Pan et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectenterodiol
dc.subjectenterolactone
dc.subjectflax essence
dc.subjectglucose
dc.subjecthemoglobin A1c
dc.subjectinsulin
dc.subjectisoflavone derivative
dc.subjectlignan
dc.subjectlipid
dc.subjectplacebo
dc.subjectlignan
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectChina
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectcrossover procedure
dc.subjectdiarrhea
dc.subjectdouble blind procedure
dc.subjectdrug bioavailability
dc.subjectdrug efficacy
dc.subjectdrug excretion
dc.subjectfemale
dc.subjectflatulence
dc.subjectglycemic control
dc.subjecthuman
dc.subjecthypercholesterolemia
dc.subjectinsulin resistance
dc.subjectinsulin sensitivity
dc.subjectlinseed
dc.subjectlipid blood level
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectnausea
dc.subjectnon insulin dependent diabetes mellitus
dc.subjectrandomized controlled trial
dc.subjecttreatment duration
dc.subjectchemistry
dc.subjectdiet therapy
dc.subjectflax
dc.subjectmiddle aged
dc.subjectnon insulin dependent diabetes mellitus
dc.subjecttreatment outcome
dc.subjectAnimalia
dc.subjectAged
dc.subjectCross-Over Studies
dc.subjectDiabetes Mellitus, Type 2
dc.subjectDouble-Blind Method
dc.subjectFemale
dc.subjectFlax
dc.subjectHumans
dc.subjectLignans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPlacebos
dc.subjectTreatment Outcome
dc.typeArticle
dc.contributor.departmentLIFE SCIENCES INSTITUTE
dc.description.doi10.1371/journal.pone.0001148
dc.description.sourcetitlePLoS ONE
dc.description.volume2
dc.description.issue11
dc.description.pagee1148
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pone_0001148.pdf283 kBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons